Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Sabatolimab Showcases Similar Pharmacokinetics Across 400- and 800-mg Doses in MDS/AML
December 6th 2020Sabatolimab demonstrated comparable pharmacokinetic activity at doses of 200 mg every 2 weeks and 800 mg every 4 weeks in combination with hypomethylating agents in patients with acute myeloid leukemia and myelodysplastic syndrome.
Talquetamab Showcases Promising Safety, Efficacy in Heavily Pretreated Myeloma
December 6, 2020 — The off-the-shelf DuoBody® IgG4 PAA binding antibody talquetamab has elicited a high response rate with a tolerable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma.
BCMA/CD3 Bispecific Antibody REGN5458 Elicits Early, Deep Responses in Relapsed/Refractory Myeloma
December 6th 2020December 6, 2020 — REGN5458, a BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.
Asciminib Emerges as a Potential Treatment Alternative in Heavily Pretreated CML
December 6th 2020December 6, 2020 — The investigational TKI asciminib was found to be a safe and effective treatment for patients with chronic myeloid leukemia without any alternatives in clinical practice, particularly those with prior TKI intolerance and those who achieved prior complete cytogenetic response.
December 6, 2020 — The BCMA and CD3 bispecific T-cell redirecting antibody TNB-383B elicited significant responses when administered at a higher dose level and was well tolerated at all doses examined in heavily pretreated patients with relapsed/refractory multiple myeloma.
Patients With Hematologic Cancers at Increased Risk for Adverse COVID-19 Outcomes
December 6, 2020 — Patients with hematologic malignancies are at increased risk for significant morbidity and mortality from coronavirus disease 2019, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment
DREAMM-6 Data Set the Stage for Further Study of Belantamab Mafodotin–Based Triplet in Myeloma
December 6th 2020December 5, 2020 - The addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.
Cilta-Cel Confers 97% ORR in Relapsed/Refractory Multiple Myeloma
December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.
Novel CAR Engineering Overcomes Resistance in Large B-Cell Lymphoma With CD58 Loss
December 5th 2020December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.
Off-the-Shelf, SARS-CoV-2-Specific T Cells Display Antiviral Activity
December 5th 2020The effector profile of the SARS-CoV-2 virus–specific T-cell therapy, ALVR109, was polyclonal, polyfunctional, and displayed cytolytic activity against viral targets without allogeneic or autologous reactivity, suggesting ALVR109 could be a safe and effective treatment for the coronavirus disease 2019.
Anti-ICOS Antibody MEDI-570 Elicits Durable Responses in Relapsed/Refractory T-cell Lymphomas
December 5th 2020The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.
Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma
December 5th 2020ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.
First-in-Human Trial Demonstrates Clinical Activity With ROR1-Directed ADC in MCL and DLBCL
December 5th 2020December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.
bb21217 Continues to Showcase Durable Responses in Multiple Myeloma
December 5th 2020December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
Survival Benefit of Venetoclax and Rituximab in Relapsed/Refractory CLL Persists Out to Five Years
December 5th 2020December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.
Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple Myeloma
December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.
.jpg?fit=crop&auto=format)
